Procedural resources utilization and clinical outcomes with bioresorbable everolimus‐eluting scaffolds and Pt‐Cr everolimus‐eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial

Objectives We sought to compare the procedural implications of using bioresorbable everolimus‐eluting scaffolds (BVS) and Pt‐Cr everolimus‐eluting stent with abluminal bioabsorbable polymer (Synergy). Background There are important differences in the respective platforms, which could impact on proce...

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2017-08, Vol.90 (2), p.E25-E30
Main Authors: de la Torre Hernandez, Jose M., Garcia Camarero, Tamara, Lee, Dae‐Hyun, Sainz Laso, Fermin, Veiga Fernandez, Gabriela, Pino, Tania, Rubio, Silvia, Legarra, Pablo, Valdivia, Jorge R., Zueco Gil, Javier
Format: Article
Language:English
Subjects:
Absorbable Implants
Aged
bioabsorbable stent
Calcium-binding protein
Cardiovascular Agents - administration & dosage
Cardiovascular Agents - adverse effects
Clinical outcomes
Coated Materials, Biocompatible
Complications
Contrast Media - administration & dosage
Coronary Angiography
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - therapy
Coronary Thrombosis - etiology
Creatinine
Drug-Eluting Stents
drug‐eluting stent
Everolimus - administration & dosage
Everolimus - adverse effects
Female
Fluoroscopy
Humans
Implants
Incidence
Infarction
Lesions
Male
Middle Aged
Myocardial Infarction - etiology
percutaneous coronary intervention
Percutaneous Coronary Intervention - adverse effects
Percutaneous Coronary Intervention - instrumentation
Polymers - chemistry
Prospective Studies
Prosthesis Design
Radiation
Radiation Dosage
Radiation Exposure
Radiography, Interventional
Risk Factors
Spain
Thromboembolism
Thrombosis
Time Factors
Treatment Outcome
Troponin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives We sought to compare the procedural implications of using bioresorbable everolimus‐eluting scaffolds (BVS) and Pt‐Cr everolimus‐eluting stent with abluminal bioabsorbable polymer (Synergy). Background There are important differences in the respective platforms, which could impact on procedural performance, complications and outcomes. Methods A prospective, randomized single center study including consecutive patients in stable clinical condition and with lesions amenable to be treated with BVS according to predefined criteria. Patients were randomized to either treatment with BVS or Synergy. All procedural data were collected and 12 months clinical follow up conducted. Primary objectives were fluoroscopy time, median dose‐area product, contras agent volumen, and peri‐procedural troponin release. Results A total of 200 patients were included, 100 in BVS group and 100 in Synergy group. No significant differences were observed in baseline clinical and angiographic characteristics. Predilatation (97.6 vs. 25.4%; P 
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.26843